Jil C Tardiff
Professor, BIO5 Institute
Professor, Biomedical Engineering
Professor, Cellular and Molecular Medicine
Professor, Physiological Sciences - GIDP
Jil C. Tardiff, M.D., Ph.D. is a Professor of Medicine and Cellular and Molecular Medicine at the University of Arizona College of Medicine and is a member of the Clinical and Translational Institute at the BIO5 Institute. She attended the University of California at Berkeley where she completed her B.A. in Genetics in 1984. She subsequently completed her M.D. and a Ph.D. (in Cell Biology) at the Albert Einstein College of Medicine in New York City in 1992. Dr. Tardiff pursued her housestaff training at Columbia-Presbyterian Medical Center in New York City. As one of the first participants in the ABIM Clinician-Scientist pathway as a Markey Fellow, she completed an internal medicine residency coupled to a combined clinical-research fellowship in cardiovascular medicine at Columbia. In 2001 she joined the faculty at the Albert Einstein College of Medicine as an Assistant Professor of Medicine and Physiology and Biophysics. She remained on faculty at Einstein, achieving the rank of Associate Professor. In 2012, Dr. Tardiff joined the faculty at the University of Arizona College of Medicine, where she currently holds the Steven M. Gootter Endowed Chair for the Prevention of Sudden Cardiac Death. As a physician-scientist, Dr. Tardiff’s work focuses on the molecular mechanisms that underlie the development of the most common form of genetic cardiomyopathy, those caused by mutations in proteins of the cardiac sarcomere, hypertrophic cardiomyopathy (HCM). These complex disorders affect one in 500 individuals of all ages and represent the most common cause of sudden cardiac death in young people in the field. Her studies detailing the mechanisms of disease pathogenesis at the level of individual cells using transgenic mouse models has been continuously funded by the NIH since 2002 and her findings regarding disruptions in myocellular Ca2+ handling and energetics work has been cited in support of new clinical trials to evaluate novel treatment modalities for this challenging cardiomyopathy. She is a founding member of the International Thin Filament Consortium, a group of physician-scientists from many of the major academic centers in the world that focuses on bench-to-bedside studies using large, genotyped HCM cohorts. More recently, in collaboration with Professor Steven Schwartz in the Department of Chemistry at the University of Arizona, her lab has developed computational approaches to modeling and eventually predicting disease severity based on protein structure. To fully translate these basic research findings to the clinical realm, Dr. Tardiff has established a referral center for HCM (and other genetic cardiomyopathies) at the University of Arizona where patients from all over the southwest can obtain lifelong cutting edge medical care for this complex and often devastating disorder.